Renalytix Tech

New York, United States Founded: 2018 • Age: 8 yrs Listed
Provider of AI-based kidney disease diagnosis tool for healthcare professionals

About Renalytix Tech

Renalytix Tech is a publicly listed company based in New York (United States) founded in 2018 by Girish Nadkarni. Provider of AI-based kidney disease diagnosis tool for healthcare professionals. Renalytix Tech offers products and services including KidneyIntelX.dkd. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is Renalytix Clinical Laboratories. Its competitors include PaxeraHealth, Bio-AI Health and Visla Labs; 2 of its 3 listed competitors have raised funding.

Company details

Renalytix Tech was founded in 2018 in New York, United States, as a provider in the healthcare sector focused on AI-driven solutions for kidney disease. Software such as KidneyIntelX is utilized by clinics to analyze medical data, monitor treatment progress, assess risks, and generate AI-based scores for disease progression. Operations emphasize diagnostic support for professionals, with features tailored to kidney measurements and overall patient risk evaluation.

  • Headquarters New York, United States
  • Founders Girish Nadkarni
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website renalytix.com
  • Social LinkedIn X
  • Legal Name Renalytix Plc
Key Metrics
  • Annual Revenue
    $3.18 M (USD)
    26.93
    as on Jun 30, 2025
  • Net Profit
    -$21.6 M (USD)
    56.37
    as on Jun 30, 2025
  • EBITDA
    -$18.22 M (USD)
    40.22
    as on Jun 30, 2025
  • Latest Funding Round
    $20.3M (USD), Post-IPO

    Feb 2023

Products & Services of Renalytix Tech

Renalytix Tech offers a comprehensive portfolio of products and services, including KidneyIntelX.dkd.

KidneyIntelX.dkd
Diagnostic Test

Predicts risk of kidney function decline in diabetic patients over five years.

Funding Insights of Renalytix Tech

  • Total Rounds 1
  • Last Round Post-IPO β€” $20.3M
  • First Round $20.3M

    (Feb 2023)

All 1 funding rounds of Renalytix Tech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2023$20.3MPost-IPO––
–

People of Renalytix Tech

21 people are tracked at Renalytix Tech (8 in leadership, 6 in board & advisors, 7 in team).

NameRoleGroup
Girish Nadkarni
Co-FounderLeadership
James McCullough
CEOLeadership
Michael J. Donovan
Chief Medical OfficerLeadership
Christopher Scott
Chief Operating OfficerLeadership
Fergus Fleming
CTOLeadership
Adrian Rossouw
Vice President Of Information Systems And ProductLeadership
Anna Flynn
Director, Quality System Compliance And Eh&sLeadership
Elise Wilfinger
Chief Strategy & Marketing OfficerLeadership
Timothy J. Scannell
Non-Executive DirectorsBoard & advisors
Chirag R. Parikh
Non-Executive DirectorBoard & advisors
Christopher Mills
Non-Executive DirectorBoard & advisors
Erik Lium
Non-Executive DirectorBoard & advisors
Daniel J. Levangie
Non-Executive DirectorBoard & advisors
Catherine Coste
DirectorBoard & advisors
Azadeh Zabetian
Senior Medical Science LiaisonTeam
Christopher Woytovich
Clinical Laboratory Scientist (cls)Team
Anita M.
Lab Technical SupervisorTeam
Greg Schallert
Product Manager, Digital Health SolutionsTeam
Andrew Peabody
Product Manager, Digital Health SolutionsTeam
Kate Benkoczy
Manager, Health System PartnershipsTeam

1 more people are available in the full profile.

Premium access

Complete people profiles for Renalytix Tech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Renalytix Tech

Renalytix Tech is a publicly listed company on the LSE with ticker symbol RENX in UK, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Jul 2020
  • Listed onNASDAQ: RNLX
  • Listed entityRenalytix Plc
  • Exchange sectorTechnology services
  • ISINGB00BYWL4Y04
  • Share price5.35 GBX · 2026-10-14
  • Market capitalisation35,869,572.00 GBX

Financials of Renalytix Tech

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20252.3M GBP-15.8M GBP-13.3M GBP
20241.8M GBP-36.1M GBP-22.2M GBP
20232.8M GBP-37.9M GBP-34.7M GBP
20222.2M GBP-34.1M GBP-39.6M GBP
20211.1M GBP-25.8M GBP-22.8M GBP
Premium access

Detailed financial statements for Renalytix Tech

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Renalytix Tech

3 dated milestones of Renalytix Tech across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Renalytix Tech is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $20.3M.

Competitors of Renalytix Tech

Renalytix Tech has 3 listed competitors in our database, 2 of them funded. They include PaxeraHealth, Bio-AI Health and Visla Labs.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
paxerahealth.com2009Boston, United States$5.5M
AI-based medical image management solutions are offered for organizations.
bioaihealth.com2020Goffstown, United States$3.5M
AI-based disease diagnosis is provided for healthcare professionals.
visla.ai2018San Francisco, United States
Functions as an AI-based tool for disease diagnosis in healthcare.
Premium access

Detailed competitors of Renalytix Tech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Renalytix Tech

The website of Renalytix Tech (renalytix.com) receives about 3.8K visits a month.

  • Monthly visits
    3.8K

    ▲ 14.3% vs previous month

Top companies in Clinical IT & Data Platforms

3 companies that operate in the same segment as Renalytix Tech (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Employee health benefits are facilitated via a cloud-based platform.
2007Plymouth Meeting, Pennsylvania, United StatesUSD 228.3 M
Healthcare appointments are booked online via Zocdoc's platform.
2007New York, New York, United StatesUSD 425.97 MUSD 4.66 M1,365
Virtual physical therapy and digital pain care solutions are provided.
2015San Francisco, California, United StatesUSD 854.44 M1,746
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Renalytix Tech

Premium access

Complete news archive for Renalytix Tech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Renalytix Tech

Renalytix Tech was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Renalytix Tech is headquartered in New York, United States. It is registered at New York, New York, United States.

Annual revenue of Renalytix Tech is $3.18M as on Jun 30, 2025.

Renalytix Tech was founded in 2018 in New York, United States, as a provider in the healthcare sector focused on AI-driven solutions for kidney disease. Software such as KidneyIntelX is utilized by clinics to analyze medical data, monitor treatment progress, assess risks, and generate AI-based scores for disease progression. Operations emphasize diagnostic support for professionals, with features tailored to kidney measurements and overall patient risk evaluation.

Renalytix Tech's top competitors include Bio-AI Health, PaxeraHealth and Visla Labs.

Renalytix Tech offers KidneyIntelX.dkd.

Yes, Renalytix Tech is publicly traded on LSE under the ticker symbol RENX.

Renalytix Tech operates through Renalytix Clinical Laboratories.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available